Ontology highlight
ABSTRACT: Purpose
The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients.Patients and methods
CPR analysis was conducted from a US payer perspective over 24 weeks for early moderate-to-severe seropositive RA patients. Efficacy data (American College of Rheumatology [ACR] improvement criteria [ACR20/50/70] and DAS28-C reactive protein <2.6) for abatacept and adalimumab were sourced from the post hoc analysis of the Early AMPLE trial (NCT02557100). Medication costs were considered assuming complete adherence. A 30% rebate was applied for adalimumab in the base case.Results
At week 24, the total per patient pharmacy cost was $26,273.34 and $21,731.18, whereas the CPR (
SUBMITTER: Park SH
PROVIDER: S-EPMC7571575 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature